Second tumors after CAR T-cell therapy are rare, and in one case of a secondary T-cell lymphoma, detailed analysis showed that the genetic construct that was used to make the CAR T cells was unrelated to the second tumor.
The New England Journal of Medicine: Search Results in Hematology/Oncology
